Long-term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) With Relapsed/Refractory (r/r) Follicular Lymphoma (FL) Treated With Tisagenlecleucel in the ELARA Trial

被引：0

作者：

Dreyling, M. ^{[1
]}

Dickinson, M. ^{[2
,3
]}

Martinez-Lopez, J. ^{[4
]}

Kolstad, A. ^{[5
]}

Butler, J. ^{[6
]}

Ghosh, M. ^{[7
]}

Popplewell, L. ^{[8
]}

Chavez, J. C. ^{[9
]}

Bachy, E. ^{[10
,11
]}

Kato, K. ^{[12
]}

Harigae, H. ^{[13
]}

Kersten, M. J. ^{[14
]}

Andreadis, C. ^{[15
]}

Riedell, P. A. ^{[16
]}

Ho, P. J. ^{[17
,18
]}

Perez-Simon, J. A. ^{[19
]}

Chen, A. I. ^{[20
]}

Nastoupil, L. J. ^{[21
]}

Tresckow, B. V. ^{[22
,23
,24
]}

Ferreri, Maria A. J. ^{[25
]}

Teshima, T. ^{[26
]}

Patten, P. E. ^{[27
,28
]}

McGuirk, J. P. ^{[29
]}

Petzer, A. ^{[30
]}

Offner, F. ^{[31
]}

Viardot, A. ^{[32
]}

Zinzani, P. L. ^{[33
,34
]}

Malladi, R. ^{[35
]}

Paule, I. ^{[36
]}

Zia, A. ^{[36
]}

Awasthi, R. ^{[37
]}

Han, X. ^{[38
]}

Germano, D. ^{[36
]}

O'Donovan, D. ^{[39
]}

Ramos, R. ^{[38
]}

Masood, A. ^{[38
]}

Thieblemont, C. ^{[40
]}

Fowler, N. ^{[41
,42
]}

Schuster, S. J. ^{[43
]}

机构：

[1] LMU Klinikum, Med Klin 3, Munich, Germany

[2] Univ Melbourne, Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[3] Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia

[4] Univ Complutense, Hosp 12 Octubre, Madrid, Spain

[5] Oslo Univ Hosp, Oslo, Norway

[6] Royal Brisbane Hosp, Herston, Qld, Australia

[7] Univ Michigan, Michigan Med, Ann Arbor, MI 48109 USA

[8] City Hope Comprehens Canc Ctr, Duarte, CA USA

[9] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematologyy, Tampa, FL USA

[10] Hosp Civils Lyon, Lyon, France

[11] Univ Claude Bernard Lyon 1, Lyon, France

[12] Kyushu Univ Hosp, Dept Hematol Oncol & Cardiovasc Med, Fukuoka, Fukuoka, Japan

[13] Tohoku Univ Hosp, Sendai, Miyagi, Japan

[14] Univ Amsterdam, Dept Hematol, Ctr Canc, Amsterdam UMC, Amsterdam, Netherlands

[15] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[16] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[17] Royal Prince Alfred Hosp, Camperdown, NSW, Australia

[18] Univ Sydney, Camperdown, NSW, Australia

[19] Univ Seville, Inst Biomed Sevilla, Univ Hosp Virgen Rocio, Dept Hematol, Seville, Spain

[20] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[21] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

[22] Univ Cologne, Med Fac, Dept Internal Med 1, Cologne, Germany

[23] Univ Cologne, Dept Internal Med 1, Univ Hosp Cologne, Cologne, Germany

[24] Univ Duisburg Essen, Univ Hosp Essen, Dept Hematol & Stem Cell Transplantat, West German Canc Ctr, Essen, Germany

[25] IRCCS San Raffaele Sci Inst, Lymphoma Unit, Milan, Italy

[26] Hokkaido Univ Hosp, Dept Hematol, Sapporo, Hokkaido, Japan

[27] Kings Coll London, Ctr Comprehens Canc, London, England

[28] Kings Coll Hosp London, Dept Haematol, London, England

[29] Univ Kansas Hosp & Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Westwood, KS USA

[30] Ordensklinikum Linz, Internal Med Hematol Stem Cell Transplantat 1, Hemostaseol & Med Oncol, Barmherzige Schwestern Elisabethinen, Linz, Austria

[31] UZ Gent, Ghent, Belgium

[32] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany

[33] IRCCS Azienda Ospedaliero Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[34] Univ Bologna, Dipartimento Med Specialist Diagnost & Sperimenta, Bologna, Italy

[35] Cambridge Univ Hosp NHS Fdn Trust, Basel, Switzerland

[36] Novartis Pharma AG, Basel, Switzerland

[37] Novartis Inst BioMed Res, E Hanover, NJ USA

[38] Novartis Pharmaceut, E Hanover, NJ USA

[39] Novartis Pharmaceut, Dublin, Ireland

[40] Hop St Louis, Paris, France

[41] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[42] BostonGene, Waltham, MA USA

[43] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1085

引用

页码：306 / 308

页数：3

共 50 条

[21] Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial
Westin, Jason R.
Tam, Constantine S.
Borchmann, Peter
Jaeger, Ulrich
McGuirk, Joseph P.
Holte, Harald
Waller, Edmund K.
Jaglowski, Samantha
Bishop, Michael R.
Andreadis, Charalambos
Foley, Stephen Ronan
Fleury, Isabelle
Ho, P. Joy
Mielke, Stephan
Teshima, Takanori
Schuster, Stephen J.
Bachanova, Veronika
Maziarz, Richard T.
Van Besien, Koen
Izutsu, Koji
Kersten, Marie Jose
Magenau, John M.
Wagner-Johnston, Nina D.
Kato, Koji
Corradini, Paolo
Han, Xia
Tiwari, Ranjan
Agoulnik, Sergei
Eldjerou, Lamis K.
Pacaud, Lida Bubuteishvili
Salles, Gilles A.
BLOOD, 2019, 134
[22] Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma patients in the JULIET trial
Westin, J.
Tam, C. S.
Borchmann, P.
Jaeger, U.
McGuirk, J. P.
Holte, H.
Waller, E. K.
Jaglowski, S.
Bishop, M. R.
Andreadis, C.
Foley, S. R.
Fleury, I
Ho, P. J.
Mielke, S.
Teshima, T.
Schuster, S. J.
Bachanova, V
Maziarz, R. T.
Besien, K., V
Izutsu, K.
Kersten, M. J.
Wagner-Johnston, N. D.
Kato, K.
Corradini, P.
Han, X.
Tiwari, R.
Eldjerou, L. K.
Pacaud, L. B.
Salles, G. A.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 58 - 58
[23] Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy iN Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial
Westin, Jason
Tam, Constantine
Borchmann, Peter
Jaeger, Ulrich
McGuirk, Joseph
Holte, Harald
Waller, Edmund
Jaglowski, Samantha
Bishop, Michael
Andreadis, Charalambos
Foley, Stephen Ronan
Fleury, Isabelle
Ho, P. Joy
Mielke, Stephan
Teshima, Takanori
Schuster, Stephen
Bachanova, Veronika
Maziarz, Richard
Van Besien, Koen
Izutsu, Koji
Kersten, Marie Jose
Magenau, John
Wagner-Johnston, Nina
Kato, Koji
Corradini, Paolo
Han, Xia
Tiwari, Ranjan
Agoulnik, Sergei
Elderjou, Lamis
Pacaud, Lida Bubuteishvili
Salles, Gilles
BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 48 - 51
[24] Results from the follicular lymphoma (FL) outcomes in patients (pts) with relapsed/refractory (R/R) disease treated with systemic therapy in a real-world assessment (FLORA) study.
Luminari, Stefano
Harnett, James
Thieblemont, Catherine
Prochazka, Katharina
Townsend, William
Radford, John
Serna, Angel
Jalbert, Jessica J.
Kamat, Siddhesh
Wang, Joy
Ambati, Srikanth R.
Mohamed, Hesham
Chaudhry, Aafia
Sanz, Hector
Hermans, Ruben
Maissenhaelter, Benedikt
Hampp, Christian
Bachy, Emmanuel
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[25] TRANSCEND FL: phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)
Borchmann, Peter
Morschhauser, Franck
Dahiya, Saurabh
Palomba, M. Lia
Garcia-Sancho, Alejandro Martin
Reguera Ortega, Juan Luis
Kuruvilla, John
Jaeger, Ulrich
Cartron, Guillaume
Izutsu, Koji
Dreyling, Martin
Kahl, Brad
Ghesquieres, Herve
Ardeshna, Kirit
Goto, Hideki
Barbui, Anna Maria
Abramson, Jeremy S.
Fleury, Isabelle
Mielke, Stephan
Farazi, Thalia
Fasan, Omotayo
Lymp, James
Vedal, Min
Nishii, Rina
Avilion, Ariel
Papuga, Jessica
Nastoupil, Loretta J.
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 142 - 143
[26] Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL).
Jacobson, Caron Alyce
Hemmer, Michael T.
Hu, Zhen-Huan
Frank, Matthew Joshua
Popplewell, Leslie
Ahmed, Nausheen
Lin, Yi
Best, Timothy
Beygi, Sara
Miao, Harry H.
Fu, Christine
Sun, Fang
Xu, Hairong
Pasquini, Marcelo C.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[27] Primary analysis of the Phase 2 ELM-2 study: Odronextamab in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL)
Chong, Geoffrey
Taszner, Michal
Novelli, Silvana
Cho, Seok-Goo
Villasboas, Jose C.
Ubieto, Ana Jimenez
Tessoulin, Benoit
Poon, Michelle
Tucker, David
Walewski, Jan
Song, Yuqin
Bachy, Emmanuel
Guidez, Stephanie
Alonso, Aranzazu
Jagadeesh, Deepa
Luminari, Stefano
Mayer, Laura Magnano
Iskierka-Jazdzewska, Elzbieta
Tani, Monica
Cai, Jingxian
Uppala, Amulya
Shariff, Saleem
Brouwer-Visser, Jurriaan
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth
Kim, Tae Min
CANCER RESEARCH, 2024, 84 (07)
[28] Long Term Durable Responses in Relapsed/Refractory (r/r) ALL, DLBCL, and FL Patients Treated with Tisagenlecleucel and Its Association with Persistence of CAR T-Cells
Awasthi, Rakesh
Waldron, Edward
Grupp, Stephan
Pulsipher, Michael A.
Bader, Peter
Schuster, Stephen J.
Maziarz, Richard T.
Waller, Edmund K.
Jaeger, Ulrich
Thieblemont, Catherine
Dreyling, Martin
Fowler, Nathan
Maier, Harald Jakob
Willert, Jennifer
BLOOD, 2023, 142
[29] Primary Clinical Response of Relmacabtagene Autoleucel in Adults with Relapsed/Refractory Follicular Lymphoma (r/r FL) in China
Song, Yuqin
Ying, Zhitao
Yang, Haiyan
Guo, Ye
Li, Wenyu
Zou, Dehui
Wu, Jianqiu
Yang, Su
Zhang, Pian
Ma, Meilin
Zhou, Zisong
Zheng, Hongxia
Zhu, Jun
BLOOD, 2021, 138
[30] Correlation of Bridging Therapy (BT) and Lymphodepleting Chemotherapy (LDC) with clinical outcomes in patients (pts) with relapsed/refractory Diffuse Large B-cell Lymphoma (r/r DLBCL) treated with tisagenlecleucel
Andreadis, C.
Tam, C. S.
Borchmann, P.
Jaeger, U.
McGuirk, J. P.
Holte, H.
Waller, E. K.
Jaglowski, S.
Bishop, M. R.
Foley, S. R.
Westin, J. R.
Fleury, I
Ho, P. J.
Mielke, S.
Teshima, T.
Salles, G. A.
Schuster, S. J.
Bachanova, V
Maziarz, R. T.
Besien, K., V
Izutsu, K.
Wagner-Johnston, N. D.
Kato, K.
Corradini, P.
Tiwari, R.
Awasthi, R.
Lawniczek, T.
Eldjerou, L. K.
Kersten, M. J.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 62 - 63

← 1 2 3 4 5 →